Castle Biosciences (CSTL) Total Debt (2018 - 2026)

Castle Biosciences has disclosed Total Debt across 7 years of filings, most recently posting $13.0 million for Q2 2026.

• In Q2 2026, Total Debt rose 8.41% year-over-year to $13.0 million; the TTM figure through Jun 2026 stood at $13.0 million (up 8.41% YoY), while the FY2025 annual figure was $10.5 million, up 1.68% from the prior year.
• Total Debt came in at $13.0 million for Q2 2026 at Castle Biosciences, up from $11.7 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $20.8 million in Q1 2022 to a low of $10.0 million in Q1 2024.
• Average Total Debt over 4 years is $11.8 million, with a median of $10.5 million recorded in 2025.
• The largest YoY upside for Total Debt was 19.74% in 2025 against a maximum downside of 0.34% in 2025.
• Over 4 years, Total Debt stood at $20.8 million in 2022, then plunged by 50.59% to $10.3 million in 2024, then increased by 1.68% to $10.5 million in 2025, then grew by 24.04% to $13.0 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $13.0 million in Q2 2026, $11.7 million in Q1 2026, and $10.5 million in Q4 2025.